Counterpain PXM Versus Diclofenac Versus Piroxicam

by palligoelme@gmail.com | Mar 16, 2026 | Clinical Trials

​ Conditions: Ankle Sprain; Back Pain; Osteoarthritis (OA) of the Knee; Tennis Elbow; Runner’s Knee Interventions: Drug: Piroxicam plus Counterirritant (brand name Counterpain® PXM).; Drug: Diclofenac Sodium 10 mg (Brand Name Hotin® DCL); Drug: Piroxicam 0.5%...

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

by palligoelme@gmail.com | Mar 13, 2026 | Clinical Trials

​ Conditions: B-cell Non Hodgkin Lymphoma Interventions: Biological: 1 X 10^6 cells/kg; Biological: 2.5 X 10^6 cells/kg; Biological: Dose expansion: The maximum tolerated dose of CAR-T cells Sponsors: Medical College of Wisconsin Not yet recruiting Conditions: B-cell...

Mobile Shared Decision-Making Program for ICU Caregivers

by palligoelme@gmail.com | Mar 13, 2026 | Clinical Trials

​ Conditions: Terminally Ill Patients Interventions: Other: Experimental: Mobile technology devices; Other: Placebo Comparator: Placebo Sponsors: CHIA-HUI MA; Mackay Memorial Hospital Completed Conditions: Terminally Ill Patients Interventions: Other: Experimental:...

Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor

by palligoelme@gmail.com | Mar 13, 2026 | Clinical Trials

​ Conditions: Neuroendocrine (NE) Tumors Interventions: Other: quality of life questionnaire, treatment side effect follow up Sponsors: Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting Conditions: Neuroendocrine (NE) Tumors Interventions: Other: quality...

Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma

by palligoelme@gmail.com | Mar 13, 2026 | Clinical Trials

​ Conditions: Glioma; Diffuse Glioma; Recurrent Gliomas Interventions: Drug: Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma....